Meridian Bioscience (Meridian Bioscience) Risk Assessment

View and export this data going back to 1986. Start your Free Trial

What is Meridian Bioscience Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Meridian Bioscience is: No Data: Cannot be evaluated.

Competitive Comparison of Meridian Bioscience's Risk Assessment

For the Diagnostics & Research subindustry, Meridian Bioscience's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Meridian Bioscience's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Meridian Bioscience's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Meridian Bioscience's Risk Assessment falls into.

Meridian Bioscience (NAS:VIVO) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Meridian Bioscience Risk Assessment Related Terms

Thank you for viewing the detailed overview of Meridian Bioscience's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Meridian Bioscience (Meridian Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Meridian Bioscience Inc (NAS:VIVO) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

3471 River Hills Drive, Cincinnati, OH, USA, 45244

Website

https://www.meridianbioscience.com

Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The Life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. It also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. The entity has a business presence in the US and other countries.

Executives

Julie Diana Smith	officer: Sr VP, Controller, PAO	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
John P. Kenny	director, officer: Chief Executive Officer	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Andrew S. Kitzmiller	officer: EVP & CFO	ONE BATESVILLE BLVD., BATESVILLE IN 47006
Bryan T Baldasare	officer: Interim CFO & Chief Acctg Off	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Rice John Mccune Jr.	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Bihl Anthony P Iii	director	807 SMITH RIDGE ROAD, NEW CANAAN CT 06840
Tony Serafini-lamanna	officer: Executive VP-Diagnostics	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Felicia Williams	director	C/O MACY'S, INC., 151 WEST 34TH STREET, NEW YORK NY 10001
John Mcilwraith	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
David Phillips	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
James M. Anderson	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Dwight E Ellingwood	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Lawrence Baldini	officer: Exec VP, Operations & IS	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric S. Rasmussen	officer: EVP, Bus. Development/Strategy	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Lourdes Weltzien	officer: EVP, Life Science	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244